Literature DB >> 17135811

ADCS Prevention Instrument Project: quality of life assessment (QOL).

Marian B Patterson1, Peter J Whitehouse, Steven D Edland, Susie A Sami, Mary Sano, Kathleen Smyth, Myron F Weiner.   

Abstract

Information about quality of life (QOL) is valuable in evaluating pharmaceutical agents but it is not adequately assessed in many dementia drug trials. In prevention trials, following participants to conversion to AD requires QOL scales appropriate for both normal and cognitively impaired individuals. Our objective was to evaluate the utility of several scales for subject or informant QOL assessment: Quality of Life-AD; Quality of Life Activity Inventory; SF-36; SF-12 (a shortened version of the SF-36); and Satisfaction with Life Scale. Measurements were collected from 644 subject-study partner pairs, half of whom completed the instruments at the clinic and half at home. Three-month test-retest data were collected. Scales administered at home or in clinic did not differ significantly. Subject self-ratings showed a wide range for all scales. Test-retest intraclass coefficients ranged from 0.67 to 0.77. Moderately high interscale associations suggest that the scales are measuring common aspects of QOL but are not equivalent. Furthermore, they differed with respect to associations with demographic variables and QOL determinants. We conclude that the QOL scores at baseline show sufficient range and reliability to suggest they will have utility in tracking QOL through conversion to dementia.

Entities:  

Mesh:

Year:  2006        PMID: 17135811     DOI: 10.1097/01.wad.0000213874.25053.e5

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  10 in total

1.  Family quality of life in dementia: a qualitative approach to family-identified care priorities.

Authors:  Jamie K Ducharme; David S Geldmacher
Journal:  Qual Life Res       Date:  2011-01-30       Impact factor: 4.147

2.  Monitoring my multiple sclerosis: a patient-administered health-assessment scale.

Authors:  Elsie E Gulick; Marie Namey; June Halper
Journal:  Int J MS Care       Date:  2011

3.  Pilot study to show the feasibility of a multicenter trial of home-based assessment of people over 75 years old.

Authors:  Mary Sano; Susan Egelko; Steven Ferris; Jeffrey Kaye; Tamara L Hayes; James C Mundt; Michael Donohue; Sarah Walter; Shelly Sun; Luis Sauceda-Cerda
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jul-Sep       Impact factor: 2.703

4.  The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults.

Authors:  Clara Li; Judith Neugroschl; Xiaodong Luo; Carolyn Zhu; Paul Aisen; Steven Ferris; Mary Sano
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  Developing dementia prevention trials: baseline report of the Home-Based Assessment study.

Authors:  Mary Sano; Susan Egelko; Michael Donohue; Steven Ferris; Jeffrey Kaye; Tamara L Hayes; James C Mundt; Chung-Kai Sun; Silvia Paparello; Paul S Aisen
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Oct-Dec       Impact factor: 2.703

Review 6.  Quality of life in glaucoma and three other chronic diseases: a systematic literature review.

Authors:  Tim Mills; Simon K Law; John Walt; Patricia Buchholz; Jan Hansen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

7.  Dementia patient suffering and caregiver depression.

Authors:  Richard Schulz; Kathleen A McGinnis; Song Zhang; Lynn M Martire; Randy S Hebert; Scott R Beach; Bozena Zdaniuk; Sara J Czaja; Steven H Belle
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Apr-Jun       Impact factor: 2.703

8.  [Quality of life in mild cognitive impairment, patients with different stages of Alzheimer disease and healthy control subjects].

Authors:  Elisabeth M Weiss; Ilona Papousek; Andreas Fink; Theresa Matt; Josef Marksteiner; Eberhard A Deisenhammer
Journal:  Neuropsychiatr       Date:  2012-07-27

9.  Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials.

Authors:  Lon S Schneider; Rema Raman; Frederick A Schmitt; Rachelle S Doody; Philip Insel; Christopher M Clark; John C Morris; Barry Reisberg; Ronald C Petersen; Steven H Ferris
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Jul-Sep       Impact factor: 2.703

10.  Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease.

Authors:  Lori Frank; William R Lenderking; Kellee Howard; Marc Cantillon
Journal:  Alzheimers Res Ther       Date:  2011-12-09       Impact factor: 6.982

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.